<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Matern Child Health J</journal-id><journal-id journal-id-type="iso-abbrev">Matern Child Health J</journal-id><journal-title-group><journal-title>Maternal and Child Health Journal</journal-title></journal-title-group><issn pub-type="ppub">1092-7875</issn><issn pub-type="epub">1573-6628</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39987298</article-id><article-id pub-id-type="pmc">PMC12098476</article-id>
<article-id pub-id-type="publisher-id">4072</article-id><article-id pub-id-type="doi">10.1007/s10995-025-04072-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Changes in Hospital Care of Newborn Infants with Trisomy 13</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Ignatz-Hoover</surname><given-names>Allison O.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1475-2145</contrib-id><name><surname>Farghaly</surname><given-names>Mohsen A. A.</given-names></name><address><email>fargham@ccf.org</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Crist</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Abdalla</surname><given-names>Alshimaa</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Aly</surname><given-names>Hany</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Mohamed</surname><given-names>Mohamed A.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03xjacd83</institution-id><institution-id institution-id-type="GRID">grid.239578.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 0675 4725</institution-id><institution>Neonatal Intensive Care Unit, </institution><institution>Cleveland Clinic Children&#x02019;s Hospital, </institution></institution-wrap>9500 Euclid Avenue #M31, Cleveland, OH 44195 USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/048qnr849</institution-id><institution-id institution-id-type="GRID">grid.417764.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 4699 3028</institution-id><institution>Pediatrics Department, </institution><institution>Aswan University, </institution></institution-wrap>Aswan, Egypt </aff></contrib-group><pub-date pub-type="epub"><day>22</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>22</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>29</volume><issue>5</issue><fpage>622</fpage><lpage>627</lpage><history><date date-type="accepted"><day>10</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Objective</title><p id="Par1">To examine the changes over recent years in neonatal survival to discharge, prevalence of adverse events, surgical procedures, tracheostomy and/or gastrostomy tube (G-tube) placement, and length of stay (LOS) in infants with Trisomy 13.</p></sec><sec><title>Methods</title><p id="Par2">We identified newborn infants with Trisomy 13 in the National Inpatient Sample in the years 2003&#x02013;2018. We calculated prevalence of associated conditions. We examined procedures done, and common adverse events associated with each condition, survival rates, and LOS. We also calculated changes in trends over the years.</p></sec><sec><title>Results</title><p id="Par3">The study identified 5792 newborn infants with Trisomy 13. Mortality during neonatal period was 58%. There was no significant change in mortality trends over the years, (p&#x02009;&#x0003c;&#x02009;0.001). Average LOS was 10 (+&#x02009;34) days which had significantly increased over recent years (p&#x02009;&#x0003c;&#x02009;0.001) and it was highest in conditions of NEC followed by gastrointestinal anomalies and sepsis. Among survivors, 2% were discharged with tracheostomy and 9% with G-tubes. LOS was significantly increased in association with these procedures.</p></sec><sec><title>Conclusion</title><p id="Par4">There was a slight decrease in infants admitted to neonatal intensive care units with Trisomy 13 over recent years. In-hospital neonatal mortality was unchanged. However, there was a significant increase in LOS, which was increased with procedures such as tracheostomy and G-tube placement, which may reflect a trend toward increasing interventions without a corresponding improvement in mortality.</p></sec></abstract><abstract id="Abs2" abstract-type="Significance"><title>Significance</title><p>What is already known on this subject?</p><p>What this study adds?</p><p>The outcomes of infants born with Trisomy 13 have changed over recent years as more centers perform surgical procedures.</p><p>There is a significant increase in length of inpatient stay with increasing procedures such as tracheostomy and G-tube placement, but without a corresponding improvement in mortality.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>NICU ethics</kwd><kwd>Palliative</kwd><kwd>Trisomy 13</kwd><kwd>Patau syndrome</kwd><kwd>Genetic</kwd><kwd>Counseling</kwd><kwd>Chromosomal disorder</kwd><kwd>Neonate</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Science+Business Media, LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Trisomy 13 (T13), also known as Patau syndrome, is a rare genetic condition that occurs when a person has an extra copy of chromosome 13 in some or all of their cells, and it is associated with multiple characteristic anomalies, severe neurocognitive deficits, and high rates of infant mortality (Springett et al., <xref ref-type="bibr" rid="CR11">2015</xref>). Some studies showed an increase in survival of infants diagnosed with T13, which was substantially higher among those undergoing cardiac surgery; in a United States population-based study using 1997&#x02013;2007 data from nine states, 5-year survival was 9.7% (Meyer et al., <xref ref-type="bibr" rid="CR5">2016</xref>). A large Canadian study reported similar findings, utilizing 1991&#x02013;2012 data from multiple databases in the single-payer health care system. One-year survival was 19.8%; furthermore, ten-year survival was 12.9% (Nelson et al., <xref ref-type="bibr" rid="CR7">2016</xref>). In a study using 1982&#x02013;2008 data from the multicenter registry of the Pediatric Cardiac Care Consortium, median survival (conditioned to hospital discharge) was 14.8&#x000a0;years in 29 patients with T13 (Peterson et al., <xref ref-type="bibr" rid="CR9">2017</xref>).</p><p id="Par6">T13 has been considered a lethal condition, but over the past decade a number of studies have demonstrated improved long-term survival as more infants received medical and surgical interventions (Janvier et al., <xref ref-type="bibr" rid="CR2">2012</xref>). At the same time, as arguably both a cause and an effect of this practice shift, there has been a dramatic shift in how pediatric ethicists and the larger pediatric community view decision-making for T13. A few major articles have appeared in the pediatric ethics literature in the past several years (Kett, <xref ref-type="bibr" rid="CR3">2020</xref>; Pyle et al., <xref ref-type="bibr" rid="CR10">2018</xref>), including a piece by John Lantos (<xref ref-type="bibr" rid="CR4">2016</xref>), who argues that T13 compromises a gray area, in which survival rates are low but not too low, and neurocognitive impairment is severe but not total, and thus parental values should drive decisions.</p><p id="Par7">Still, though, most studies on long-term survival for T13 have utilized data prior to more recent practices of surgical repair for complex cardiac defects and have not consistently reported on trends in healthcare utilization and in-hospital costs for this population. We hypothesize that there is a practice change in the management of T13 that involving more proactive procedures/interventions in the neonatal period. This study, then, aims to examine the changes over recent years in neonatal survival to discharge, prevalence of adverse events, surgical procedures, tracheostomy and/or G-tube placement, and LOS in infants with T13.</p></sec><sec id="Sec2"><title>Methods</title><p id="Par8">We identified newborn infants diagnosed with T13 in the National Inpatient Sample (NIS), and its Kids' Inpatient Database (KID) subversion. NIS is a de-identified, publicly available inpatient healthcare database produced by the Health Cost and Utilization Project (HCUP). It contains data of more than 7 million hospital stays each year. In this study, we used the NIS for the years 2003&#x02013;2018. All types of neonatal admissions were included whether they were direct admissions the neonatal intensive care units (NICUs), admissions from the emergency room or transfers from other hospitals. To avoid duplicate inclusion, infants who were transferred out of the delivery hospital were excluded.</p><p id="Par9">Infants with T13 were identified in the dataset using the respective International Classification of Diseases codes&#x02014;9th version (ICD-9) and 10th version (ICD-10. Similarly, infants developed postnatal condition, or adverse effects were identified using respective ICD-9 and ICD-10 codes. This study involved publicly available de-identified data; therefore, it was exempted from review by the Institutional Review Board (IRB).</p><p id="Par10">We calculated prevalence of commonly associated conditions such as congenital heart disease (CHD), diaphragmatic hernias, central nervous system (CNS), pulmonary or gastrointestinal (GI) anomalies, or abdominal wall defects (AWD). We examined procedures done, and common adverse events such as sepsis, necrotizing enterocolitis (NEC), pulmonary hemorrhage, or pulmonary hypertension, mortality associated with each condition, and length of stay (LOS) in the overall sample and among those who were discharged home or transferred to a chronic care facility. We also calculated changes in trends over the years. We used logistic regression analysis to examine the association of different concurrent congenital anomalies or postnatal adverse effects while controlling for confounding variables such as birth weight, gestational age, sex, race, the presence of other previously mentioned congenital anomalies and medical conditions. We did not consider time series analysis methods as data used lacks the disposition of these infants after discharge.</p></sec><sec id="Sec3"><title>Results</title><p id="Par11">The study identified 66,207,242 newborn infants. Of them, 5792 (approximately 0.01%) were diagnosed with T13 (8.7 in 100,000 live newborns). There was a mildly significant decrease in the prevalence of T13 over the years (p&#x02009;&#x0003c;&#x02009;0.001, Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a). CHD were the most common associated anomaly (49%), followed by CNS anomalies (23%) and pulmonary hypertension (6.8%), Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Trends in Trisomy 13 over 2003&#x02013;2018 in the United States National Inpatient Database</p></caption><graphic xlink:href="10995_2025_4072_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Characteristics of infants with Trisomy 13, associated mortality and length of stay in the United States National Inpatient Database in the years 2003&#x02013;2018.<sup>1</sup></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left" rowspan="2">Frequency<sup>1</sup><break/>(95% CI)</th><th align="left" rowspan="2">Mortality<sup>2</sup><break/>(95% CI)</th><th align="left" colspan="2">Length of Stay in days<sup>3</sup></th></tr><tr><th align="left"/><th align="left">Overall</th><th align="left">Among survivors<sup>4</sup></th></tr></thead><tbody><tr><td align="left">Overall sample</td><td align="left">n&#x02009;=&#x02009;5792</td><td align="left">58% (56&#x02013;59)</td><td align="left">10 (34)</td><td align="left">16 (43)</td></tr><tr><td align="left" colspan="5">Demographic characteristics</td></tr><tr><td align="left">&#x000a0;Birth weight&#x02009;&#x0003c;&#x02009;1500&#x000a0;g</td><td align="left">11 (10&#x02013;12)</td><td align="left">87% (84&#x02013;90)</td><td align="left">8 (36)</td><td align="left">39 (64)</td></tr><tr><td align="left">&#x000a0;Birth weight&#x02009;&#x0003e;&#x02009;1500&#x000a0;g</td><td align="left">89 (87&#x02013;91)</td><td align="left">56% (54&#x02013;58)</td><td align="left">10 (33)</td><td align="left">15 (41)</td></tr><tr><td align="left">&#x000a0;Gestational age&#x02009;&#x0003c;&#x02009;28&#x000a0;week</td><td align="left">6 (5&#x02013;7)</td><td align="left">92% (85&#x02013;99)</td><td align="left">7 (47)</td><td align="left">67 (151)</td></tr><tr><td align="left">&#x000a0;Gestational age&#x02009;&#x0003e;&#x02009;28&#x000a0;week</td><td align="left">94 (92&#x02013;96)</td><td align="left">54% (52&#x02013;56)</td><td align="left">10 (33)</td><td align="left">15 (40)</td></tr><tr><td align="left">&#x000a0;Sex female</td><td align="left">51 (50&#x02013;52)</td><td align="left">52% (51&#x02013;53)</td><td align="left">11 (37)</td><td align="left">16 (47)</td></tr><tr><td align="left">&#x000a0;Sex male</td><td align="left">49 (48&#x02013;50)</td><td align="left">64% (63&#x02013;65)</td><td align="left">90 (30)</td><td align="left">15 (37)</td></tr><tr><td align="left">&#x000a0;Race/ethnicity</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;Whites</td><td align="left">35 (33&#x02013;37)</td><td align="left">56% (54&#x02013;58)</td><td align="left">8 (32)</td><td align="left">14 (44)</td></tr><tr><td align="left">&#x000a0;&#x000a0;African American</td><td align="left">15 (12&#x02013;18)</td><td align="left">57% (55&#x02013;59)</td><td align="left">14 (46)</td><td align="left">19 (55)</td></tr><tr><td align="left">&#x000a0;&#x000a0;Hispanic Latino</td><td align="left">20 (19&#x02013;21)</td><td align="left">58% (57&#x02013;59)</td><td align="left">9 (24)</td><td align="left">14 (29)</td></tr><tr><td align="left">&#x000a0;&#x000a0;Asian/Pacific Islander</td><td align="left">2.4 (1.9&#x02013;2.9)</td><td align="left">66% (61&#x02013;71)</td><td align="left">8 (16)</td><td align="left">12 (16)</td></tr><tr><td align="left">&#x000a0;&#x000a0;Native American</td><td align="left">0.6 (0.5&#x02013;0.7)</td><td align="left">48% (44&#x02013;52)</td><td align="left">15 (34)</td><td align="left">21 (42)</td></tr><tr><td align="left">&#x000a0;&#x000a0;Others</td><td align="left">27 (25&#x02013;29)</td><td align="left">60% (59&#x02013;61)</td><td align="left">11 (33)</td><td align="left">17 (43)</td></tr><tr><td align="left" colspan="5">Associated congenital anomalies</td></tr><tr><td align="left">&#x000a0;Congenital heart diseases</td><td align="left">49 (47&#x02013;51)</td><td align="left">55% (54&#x02013;56)</td><td align="left">13 (35)</td><td align="left">17 (39)</td></tr><tr><td align="left">&#x000a0;Nervous system anomalies</td><td align="left">23 (21&#x02013;25)</td><td align="left">64% (61&#x02013;67)</td><td align="left">8 (26)</td><td align="left">12 (33)</td></tr><tr><td align="left">&#x000a0;Hydrocephalus</td><td align="left">5.0 (4&#x02013;6)</td><td align="left">69% (68&#x02013;70)</td><td align="left">10 (32)</td><td align="left">15 (41)</td></tr><tr><td align="left">&#x000a0;Abdominal wall defects</td><td align="left">4.5 (4&#x02013;5)</td><td align="left">65% (63&#x02013;67)</td><td align="left">4 (9)</td><td align="left">3 (6)</td></tr><tr><td align="left">&#x000a0;Lung anomalies</td><td align="left">4.0 (3.5)</td><td align="left">77% (76&#x02013;78)</td><td align="left">12 (45)</td><td align="left">32 (65)</td></tr><tr><td align="left">&#x000a0;Diaphragmatic hernia</td><td align="left">2.0 (1&#x02013;3)</td><td align="left">75% (74&#x02013;77)</td><td align="left">90 (41)</td><td align="left">20 (34)</td></tr><tr><td align="left">&#x000a0;Intestinal atresia</td><td align="left">0.5 (0.3&#x02013;0.6)</td><td align="left">50% (48&#x02013;52)</td><td align="left">29 (54)</td><td align="left">41 (61)</td></tr><tr><td align="left" colspan="5">Common adverse outcomes</td></tr><tr><td align="left">&#x000a0;Early or late sepsis</td><td align="left">10 (9&#x02013;11)</td><td align="left">53% (52&#x02013;54)</td><td align="left">26 (58)</td><td align="left">32 (70)</td></tr><tr><td align="left">&#x000a0;Pulmonary hypertension</td><td align="left">6.8 (5.9&#x02013;7.6)</td><td align="left">59% (56&#x02013;62)</td><td align="left">21 (49)</td><td align="left">27 (54)</td></tr><tr><td align="left">&#x000a0;Necrotizing enterocolitis</td><td align="left">3.1 (2.5&#x02013;3.7)</td><td align="left">57% (56&#x02013;58)</td><td align="left">42 (77)</td><td align="left">56 (87)</td></tr><tr><td align="left">&#x000a0;Pulmonary hemorrhage</td><td align="left">0.4 (0.2&#x02013;0.4)</td><td align="left">91% (91&#x02013;92)</td><td align="left">28 (45)</td><td align="left">n/a</td></tr><tr><td align="left">Common procedures</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Gastrostomy tube</td><td align="left">5.0 (4.6)</td><td align="left">9.2% (8.9&#x02013;9.5)</td><td align="left">50 (82)</td><td align="left">51 (80)</td></tr><tr><td align="left">&#x000a0;Tracheostomy tube</td><td align="left">1.1 (0.8&#x02013;1.5)</td><td align="left">2.0% (1.5&#x02013;2.5)</td><td align="left">96 (94)</td><td align="left">91 (98)</td></tr></tbody></table><table-wrap-foot><p><sup>1</sup>All values are in percentages/proportions</p><p><sup>2</sup>Mortality: In-hospital mortality till discharge including neonatal and post-neonatal mortality</p><p><sup>3</sup>Length of hospital stay till death or discharge in days: mean&#x02009;+&#x02009;(sd)</p><p><sup>4</sup>Survived only until discharge from the hospitals</p></table-wrap-foot></table-wrap></p><p id="Par12">Overall mortality, in-hospital, during the neonatal period was 58%. Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> Mortality was highest among those with pulmonary hemorrhage (91%), lung anomalies (77%), diaphragmatic hernia (75%), hydrocephalus (69%), abdominal wall defects (65%), other CNS anomalies (64%), and pulmonary hypertension (59%), Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. Furthermore, there was no significant change in mortality trends over the years, Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>b and Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>.<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Significant conditions associated with mortality in infants with Trisomy 13 in the United States National Inpatient Database in the years 2003&#x02013;2018</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Odds ratios</th><th align="left">95% confidence intervals</th><th align="left"><italic>p</italic> value</th></tr></thead><tbody><tr><td align="left">Female sex</td><td char="." align="char">0.7</td><td char="&#x02013;" align="char">(0.5&#x02013;0.8)</td><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Gestational age&#x02009;&#x0003c;&#x02009;28&#x000a0;week</td><td char="." align="char">5.6</td><td char="&#x02013;" align="char">(2.3&#x02013;13.3)</td><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Birth weight&#x02009;&#x0003c;&#x02009;1500&#x000a0;g</td><td char="." align="char">4.2</td><td char="&#x02013;" align="char">(2.7&#x02013;6.5)</td><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Congenital heart diseases</td><td char="." align="char">0.8</td><td char="&#x02013;" align="char">(0.7&#x02013;1.0)</td><td char="." align="char">0.05</td></tr><tr><td align="left">Central nervous system anomalies</td><td char="." align="char">1.4</td><td char="." align="char">(1.0&#x02013;1.8)</td><td char="." align="char">0.02</td></tr><tr><td align="left">Lung anomalies</td><td char="." align="char">3.2</td><td char="&#x02013;" align="char">(1.4&#x02013;7.2)</td><td char="." align="char">0.005</td></tr></tbody></table></table-wrap><table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Changes overtime in incidence, mortality and adverse events in Trisomy 13</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Overall sample</th><th align="left">Infants born<break/>2003&#x02013;2006</th><th align="left">Infants born<break/>2015&#x02013;2018</th><th align="left">significance for trend over years<sup>1</sup></th></tr></thead><tbody><tr><td align="left">Incidence of Trisomy 13 per 100,000 hospital admission</td><td align="left">8.7</td><td align="left">9.0</td><td align="left">8.2</td><td char="." align="char">0.04</td></tr><tr><td align="left">Congenital heart diseases</td><td align="left">49%</td><td align="left">43%</td><td align="left">59%</td><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.01</td></tr><tr><td align="left">Central nervous system anomalies</td><td align="left">23%</td><td align="left">16%</td><td align="left">31%</td><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.01</td></tr><tr><td align="left">Early or late sepsis</td><td align="left">11%</td><td align="left">10%</td><td align="left">11%</td><td char="." align="char">0.12</td></tr><tr><td align="left">Pulmonary hypertension</td><td align="left">6.8%</td><td align="left">7.0%</td><td align="left">4.3%</td><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.01</td></tr><tr><td align="left">Mortality<sup>2</sup></td><td align="left">58%</td><td align="left">58%</td><td align="left">58.%</td><td char="." align="char">0.57</td></tr><tr><td align="left">Length of hospital stay<sup>3</sup></td><td align="left">10 (+&#x02009;34)</td><td align="left">7 (+&#x02009;23)</td><td align="left">12 (+&#x02009;50)</td><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.01</td></tr></tbody></table><table-wrap-foot><p><sup>1</sup>Significance for trends is calculated over years of the study (2003&#x02013;2018) in the United States National Inpatient Database</p><p><sup>2</sup>Mortality: In-hospital mortality till discharge including neonatal and post-neonatal mortality</p><p><sup>3</sup>Length of hospital stay till death or discharge in days: mean (sd)</p></table-wrap-foot></table-wrap></p><p id="Par13">Average LOS was 10 (+&#x02009;34) days. LOS had significantly increased over recent years (p&#x02009;&#x0003c;&#x02009;0.001, Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>c). Average LOS was highest in conditions of NEC followed by gastrointestinal anomalies (intestinal atresia and Hirschsprung disease), pulmonary hemorrhage and sepsis, Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.</p><p id="Par14">We further compared the change in associated major anomalies during the first four years (2003&#x02013;2006) and the last four years (2015&#x02013;2018) of the study, that could potentially contribute to increased length of stay over time (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). While mortality remained unchanged at 58%, LOS increased from 7 to 12&#x000a0;days (p&#x02009;&#x0003c;&#x02009;0.01). The diagnoses of CHD and CNS anomalies increased in two time periods.</p></sec><sec id="Sec4"><title>Discussion</title><p id="Par15">This study assessed the most recent survival data for the T13 populations, in addition to important measures of in-hospital healthcare utilization, using a large nationally representative hospital database. The study demonstrated that there was a slight decrease in infants admitted with T13 over recent years. That decline could be because of the increased prenatal genetic diagnosis and eventually elective termination of pregnancy and/or comfort care at birth.</p><p id="Par16">In addition, the study demonstrated that the in-hospital neonatal mortality was unchanged in the US over almost two decades, 2003&#x02013;2018. Meyer et al. (<xref ref-type="bibr" rid="CR5">2016</xref>), found higher survival rate at 1&#x000a0;year of age, however, their sample size was much smaller, and they included infants with various genetic expressions, had lower prevalence of CHDs and GI anomalies, and selective termination of trisomy fetuses with major malformations or pregnancy complications.</p><p id="Par17">Furthermore, this study showed that there was a significant increase in LOS, which was increased with procedures such as tracheostomy and G-tube placement, which may reflect a trend toward increasing interventions without a corresponding improvement in mortality. Our finding is consistent with a 2018 paper which did report that patients with T13 had higher inpatient medical costs, and longer LOS, but this utilized 1998&#x02013;2009 data, prior to more recent trends in cardiac surgery and only captured data for a single state, Florida (Nguyen et al., <xref ref-type="bibr" rid="CR8">2018</xref>). The previous assumption that T13 is necessarily lethal in infancy created nonintervention practices that lead to extremely low survival, which might have furthered nonintervention practices, however, as more studies demonstrated potential survival&#x02009;&#x0003e;&#x02009;1&#x000a0;year, more infants were offered life-sustaining medical treatment including surgical interventions (Nelson et al., <xref ref-type="bibr" rid="CR6">2012</xref>).<sup>10</sup> Nevertheless, unfortunately the in-hospital mortality rate remained unchanged.</p><p id="Par18">This study has several strengths. It demonstrated the changes in hospital care of neonates and infants with T13 using a recent national database in a cohort with a huge sample size representing the entire US with a robust number of sociodemographic and clinical covariates to control for potential confounders. Furthermore, the survival findings are representative as it is almost impossible to have errors in the NIS dataset related to survival and mortality (HCUP, <xref ref-type="bibr" rid="CR1">2024</xref>); and that might help parents and caregivers making decisions during antenatal consultations and/or counseling sessions. However, the study inherited a few limitations; this study could not provide a detailed long-term outcome after discharge from the hospital. In addition, it could not assess the association of survival with parent&#x02019;s wishes. Yet, the study&#x02019;s limitations have not impacted the results; as the huge sample size obtained through using the NIS datasets may overcome such limitations by creating a national average to the Trisomy 13 condition.</p><p id="Par19">In conclusion, there was a slight decrease in infants admitted to neonatal intensive care units with T13 over recent years. In-hospital neonatal mortality was unchanged. However, there was a significant increase in LOS, which was increased with procedures such as tracheostomy and G-tube placement. This may reflect a trend toward increasing interventions without a corresponding improvement in mortality, which may be practical for geneticists and neonatologists for counseling families.</p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Allison O. Ignatz-Hoover and Mohsen A. A. Farghaly have equally contributed to this work.</p></fn><fn><p>Hany Aly and Mohamed A. Mohamed shares joint senior authorship.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author Contributions</title><p>AOIH conceptualized and designed the study, and drafted and reviewed the manuscript. MAAF, AC and AA interpreted the results, and drafted, reviewed, and submitted the manuscript. HA and MAM designed the study, conducted the statistical analysis, interpreted the analysis, and drafted, reviewed, and revised the manuscript. All authors approved the final manuscript for submission.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>The authors have not disclosed any funding.</p></notes><notes notes-type="data-availability"><title>Data Availability</title><p>The data that support the findings of this study are available from the National Inpatient Sample as part of the Healthcare Cost and Utilization Project. Restrictions apply to the availability of these data, which were used under license for this study. Data are available at <ext-link ext-link-type="uri" xlink:href="https://www.hcup-us.ahrq.gov/">https://www.hcup-us.ahrq.gov/</ext-link>.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par20">All authors declare that they have no competing interests to declare.</p></notes><notes id="FPar2"><title>Ethical Approval</title><p id="Par21">Not applicable.</p></notes><notes id="FPar3"><title>Consent to Participate</title><p id="Par22">Not applicable, since data are based on previously collected data.</p></notes><notes id="FPar4"><title>Consent for Publication</title><p id="Par23">Not applicable.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><mixed-citation publication-type="other">Healthcare Cost and Utilization Project (HCUP) Agency for Healthcare Research and Quality; Rockville, MD (2024). HCUP NIS description of data elements. Retrieved September 1, 2025, from <ext-link ext-link-type="uri" xlink:href="http://www.hcup-us.ahrq.gov/nisoverview.jsp">www.hcup-us.ahrq.gov/nisoverview.jsp</ext-link></mixed-citation></ref><ref id="CR2"><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Janvier</surname><given-names>A</given-names></name><name><surname>Farlow</surname><given-names>B</given-names></name><name><surname>Wilfond</surname><given-names>BS</given-names></name></person-group><article-title>The experience of families with children with trisomy 13 and 18 in social networks</article-title><source>Pediatrics</source><year>2012</year><volume>130</volume><issue>2</issue><fpage>293</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1542/peds.2012-0151</pub-id><pub-id pub-id-type="pmid">22826570</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Janvier, A., Farlow, B., &#x00026; Wilfond, B. S. (2012). The experience of families with children with trisomy 13 and 18 in social networks. <italic>Pediatrics,</italic><italic>130</italic>(2), 293&#x02013;298.<pub-id pub-id-type="pmid">22826570</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Kett</surname><given-names>JC</given-names></name></person-group><article-title>Who is the next "Baby Doe?" from trisomy 21 to trisomy 13 and 18 and beyond</article-title><source>Pediatrics</source><year>2020</year><volume>146</volume><issue>Suppl 1</issue><fpage>S9</fpage><lpage>S12</lpage><pub-id pub-id-type="doi">10.1542/peds.2020-0818D</pub-id><pub-id pub-id-type="pmid">32737226</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Kett, J. C. (2020). Who is the next &#x0201c;Baby Doe?&#x0201d; from trisomy 21 to trisomy 13 and 18 and beyond. <italic>Pediatrics,</italic><italic>146</italic>(Suppl 1), S9&#x02013;S12.<pub-id pub-id-type="pmid">32737226</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Lantos</surname><given-names>JD</given-names></name></person-group><article-title>Trisomy 13 and 18&#x02013;treatment decisions in a stable gray zone</article-title><source>JAMA</source><year>2016</year><volume>316</volume><issue>4</issue><fpage>396</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1001/jama.2016.9470</pub-id><pub-id pub-id-type="pmid">27458943</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Lantos, J. D. (2016). Trisomy 13 and 18&#x02013;treatment decisions in a stable gray zone. <italic>JAMA,</italic><italic>316</italic>(4), 396&#x02013;398.<pub-id pub-id-type="pmid">27458943</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>RE</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Gilboa</surname><given-names>SM</given-names></name><name><surname>Ethen</surname><given-names>MK</given-names></name><name><surname>Aylsworth</surname><given-names>AS</given-names></name><name><surname>Powell</surname><given-names>CM</given-names></name><name><surname>Flood</surname><given-names>TJ</given-names></name><name><surname>Mai</surname><given-names>CT</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Canfield</surname><given-names>MA</given-names></name><name><surname>Network</surname><given-names>NBDP</given-names></name></person-group><article-title>Survival of children with trisomy 13 and trisomy 18: A multi-state population-based study</article-title><source>American Journal of Medical Genetics. Part A</source><year>2016</year><volume>170A</volume><issue>4</issue><fpage>825</fpage><lpage>837</lpage><pub-id pub-id-type="doi">10.1002/ajmg.a.37495</pub-id><pub-id pub-id-type="pmid">26663415</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Meyer, R. E., Liu, G., Gilboa, S. M., Ethen, M. K., Aylsworth, A. S., Powell, C. M., Flood, T. J., Mai, C. T., Wang, Y., Canfield, M. A., &#x00026; Network, N. B. D. P. (2016). Survival of children with trisomy 13 and trisomy 18: A multi-state population-based study. <italic>American Journal of Medical Genetics. Part A,</italic><italic>170A</italic>(4), 825&#x02013;837.<pub-id pub-id-type="pmid">26663415</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>KE</given-names></name><name><surname>Hexem</surname><given-names>KR</given-names></name><name><surname>Feudtner</surname><given-names>C</given-names></name></person-group><article-title>Inpatient hospital care of children with trisomy 13 and trisomy 18 in the United States</article-title><source>Pediatrics</source><year>2012</year><volume>129</volume><issue>5</issue><fpage>869</fpage><lpage>876</lpage><pub-id pub-id-type="doi">10.1542/peds.2011-2139</pub-id><pub-id pub-id-type="pmid">22492767</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Nelson, K. E., Hexem, K. R., &#x00026; Feudtner, C. (2012). Inpatient hospital care of children with trisomy 13 and trisomy 18 in the United States. <italic>Pediatrics,</italic><italic>129</italic>(5), 869&#x02013;876.<pub-id pub-id-type="pmid">22492767</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>KE</given-names></name><name><surname>Rosella</surname><given-names>LC</given-names></name><name><surname>Mahant</surname><given-names>S</given-names></name><name><surname>Guttmann</surname><given-names>A</given-names></name></person-group><article-title>Survival and surgical interventions for children with trisomy 13 and 18</article-title><source>JAMA</source><year>2016</year><volume>316</volume><issue>4</issue><fpage>420</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.1001/jama.2016.9819</pub-id><pub-id pub-id-type="pmid">27458947</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Nelson, K. E., Rosella, L. C., Mahant, S., &#x00026; Guttmann, A. (2016). Survival and surgical interventions for children with trisomy 13 and 18. <italic>JAMA,</italic><italic>316</italic>(4), 420&#x02013;428.<pub-id pub-id-type="pmid">27458947</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>JE</given-names></name><name><surname>Salemi</surname><given-names>JL</given-names></name><name><surname>Tanner</surname><given-names>JP</given-names></name><name><surname>Kirby</surname><given-names>RS</given-names></name><name><surname>Sutsko</surname><given-names>RP</given-names></name><name><surname>Ashmeade</surname><given-names>TL</given-names></name><name><surname>Salihu</surname><given-names>HM</given-names></name><name><surname>Drach</surname><given-names>LL</given-names></name></person-group><article-title>Survival and healthcare utilization of infants diagnosed with lethal congenital malformations</article-title><source>Journal of Perinatology : Official Journal of the California Perinatal Association</source><year>2018</year><volume>38</volume><issue>12</issue><fpage>1674</fpage><lpage>1684</lpage><pub-id pub-id-type="doi">10.1038/s41372-018-0227-3</pub-id><pub-id pub-id-type="pmid">30237475</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Nguyen, J. E., Salemi, J. L., Tanner, J. P., Kirby, R. S., Sutsko, R. P., Ashmeade, T. L., Salihu, H. M., &#x00026; Drach, L. L. (2018). Survival and healthcare utilization of infants diagnosed with lethal congenital malformations. <italic>Journal of Perinatology&#x0202f;: Official Journal of the California Perinatal Association,</italic><italic>38</italic>(12), 1674&#x02013;1684.<pub-id pub-id-type="pmid">30237475</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Peterson</surname><given-names>JK</given-names></name><name><surname>Kochilas</surname><given-names>LK</given-names></name><name><surname>Catton</surname><given-names>KG</given-names></name><name><surname>Moller</surname><given-names>JH</given-names></name><name><surname>Setty</surname><given-names>SP</given-names></name></person-group><article-title>Long-term outcomes of children with trisomy 13 and 18 after congenital heart disease interventions</article-title><source>The Annals of Thoracic Surgery</source><year>2017</year><volume>103</volume><issue>6</issue><fpage>1941</fpage><lpage>1949</lpage><pub-id pub-id-type="doi">10.1016/j.athoracsur.2017.02.068</pub-id><pub-id pub-id-type="pmid">28456396</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Peterson, J. K., Kochilas, L. K., Catton, K. G., Moller, J. H., &#x00026; Setty, S. P. (2017). Long-term outcomes of children with trisomy 13 and 18 after congenital heart disease interventions. <italic>The Annals of Thoracic Surgery,</italic><italic>103</italic>(6), 1941&#x02013;1949.<pub-id pub-id-type="pmid">28456396</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Pyle</surname><given-names>AK</given-names></name><name><surname>Fleischman</surname><given-names>AR</given-names></name><name><surname>Hardart</surname><given-names>G</given-names></name><name><surname>Mercurio</surname><given-names>MR</given-names></name></person-group><article-title>Management options and parental voice in the treatment of trisomy 13 and 18</article-title><source>Journal of Perinatology: Official Journal of the California Perinatal Association</source><year>2018</year><volume>38</volume><issue>9</issue><fpage>1135</fpage><lpage>1143</lpage><pub-id pub-id-type="doi">10.1038/s41372-018-0151-6</pub-id><pub-id pub-id-type="pmid">29977011</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Pyle, A. K., Fleischman, A. R., Hardart, G., &#x00026; Mercurio, M. R. (2018). Management options and parental voice in the treatment of trisomy 13 and 18. <italic>Journal of Perinatology: Official Journal of the California Perinatal Association,</italic><italic>38</italic>(9), 1135&#x02013;1143.<pub-id pub-id-type="pmid">29977011</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Springett</surname><given-names>A</given-names></name><name><surname>Wellesley</surname><given-names>D</given-names></name><name><surname>Greenlees</surname><given-names>R</given-names></name><name><surname>Loane</surname><given-names>M</given-names></name><name><surname>Addor</surname><given-names>MC</given-names></name><name><surname>Arriola</surname><given-names>L</given-names></name><etal/></person-group><article-title>Congenital anomalies associated with trisomy 18 or trisomy 13: A registry-based study in 16 European countries, 2000&#x02013;2011</article-title><source>American Journal of Medical Genetics. Part A</source><year>2015</year><volume>167A</volume><issue>12</issue><fpage>3062</fpage><lpage>3069</lpage><pub-id pub-id-type="doi">10.1002/ajmg.a.37355</pub-id><pub-id pub-id-type="pmid">26347425</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Springett, A., Wellesley, D., Greenlees, R., Loane, M., Addor, M. C., Arriola, L., et al. (2015). Congenital anomalies associated with trisomy 18 or trisomy 13: A registry-based study in 16 European countries, 2000&#x02013;2011. <italic>American Journal of Medical Genetics. Part A,</italic><italic>167A</italic>(12), 3062&#x02013;3069.<pub-id pub-id-type="pmid">26347425</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>